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Abstract  In  2013  new  ‘‘mouthpiece  ventilation’’  modes  are  being  introduced  to  commercially
available  portable  ventilators.  Despite  this,  there  is  little  knowledge  of  how  to  use  noninvasive
intermittent  positive  pressure  ventilation  (NIV)  as  opposed  to  bi-level  positive  airway  pressure
(PAP) and  both  have  almost  exclusively  been  reported  to  have  been  used  via  nasal  or  oro-nasal
interfaces  rather  than  via  a  simple  mouthpiece.
Non-invasive  ventilation  is  often  reported  as  failing  because  of  airway  secretion  encum-
brance, because  of  hypercapnia  due  to  inadequate  bi-level  PAP  settings,  or  poor  interface
tolerance.  The  latter  can  be  caused  by  factors  such  as  excessive  pressure  on  the  face  from
poor ﬁt,  excessive  oral  air  leak,  anxiety,  claustrophobia,  and  patient-ventilator  dys-synchrony.
Thus, the  interface  plays  a  crucial  role  in  tolerance  and  effectiveness.  Interfaces  that  cover
the nose  and/or  nose  and  mouth  (oro-nasal)  are  the  most  commonly  used  but  are  more  likely  to
cause skin  breakdown  and  claustrophobia.  Most  associated  drawbacks  can  be  avoided  by  using
mouthpiece  NIV.  Open-circuit  mouthpiece  NIV  is  being  used  by  large  populations  in  some  cen-
ters for  daytime  ventilatory  support  and  complements  nocturnal  NIV  via  ‘‘mask’’  interfaces  for
nocturnal ventilatory  support.  Mouthpiece  NIV  is  also  being  used  for  sleep  with  the  mouthpiece
ﬁxed in  place  by  a  lip-covering  ﬂange.  Small  15  and  22  mm  angled  mouthpieces  and  straw-type
mouthpieces  are  the  most  commonly  used.NIV  via  mouthpiece  is  being  used  as  an  effective  alternative  to  ventilatory  support  via  tra-
cheostomy  tube  (TMV)  and  is  associated  with  a  reduced  risk  of  pneumonias  and  other  respiratory
complications.  Its  use  facilitates  ‘‘air-stacking’’  to  improve  cough,  speech,  and  pulmonary
Abbreviations: ARF, acute respiratory failure; PAP, positive airway pressure ventilation; COPD, chronic obstructive pulmonary dis-
ease; DMD, Duchenne muscular dystrophy; (C)NIV, (continuous) non-invasive ventilation; (C)TMV, (continuous) tracheostomy mechanical
ventilation.
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compliance,  all  of  which  better  maintain  quality  of  life  for  patients  with  neuromuscular  diseases
(NMDs) than  the  invasive  alternatives.  Considering  these  beneﬁts  and  the  new  availability  of
mouthpiece  ventilator  modes,  wider  knowledge  of  this  technique  is  now  warranted.  This  review
highlights  the  indications,  techniques,  advantages  and  disadvantages  of  mouthpiece  NIV.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Ventilac¸ão  de  circuito  aberto  por  pec¸a  bucal
Resumo  Em  2013,  foram  introduzidos  novos  modos  de  «ventilac¸ão  por  pec¸a bucal»,  para  ven-
tiladores portáteis  disponíveis  comercialmente.  Apesar  disto,  há  pouco  conhecimento  sobre
como usar  a  ventilac¸ão  não  invasiva  por  pressão  positiva  intermitente  (NIV)  em  oposic¸ão  à
pressão positiva  bi-nível  (PAP)  e  ambas  têm  sido  referidas,  quase  exclusivamente,  como  sendo
utilizadas  através  de  interfaces  nasais  ou  oro-nasais,  em  vez  de  através  de  uma  simples  pec¸a
bucal.
É referido  com  frequência  a  falência  da  ventilac¸ão  não  invasiva,  devido  à  acumulac¸ão  de
secrec¸ões nas  vias  respiratórias,  devido  à  hipercapnia  por  deﬁciente  ajuste  dos  parâmetros  da
PAP ou  devido  a  uma  reduzida  tolerância  à  interface.  Esta  última  pode  ser  causada  por  fatores
como pressão  excessiva  na  face  devido  a  um  ajuste  defeituoso,  fuga  excessiva  de  ar  pela  boca,
ansiedade, claustrofobia  e  falta  de  sincronia  entre  o  doente  e  o  ventilador.  Deste  modo,  a
interface  tem  um  papel  crucial  na  tolerância  e  eﬁcácia.  Interfaces  que  cobrem  o  nariz  e/ou  a
boca (oro-nasal)  são  as  mais  habitualmente  usadas,  mas  são  as  que  apresentam  maior  propensão
a provocarem  lesões  na  pele  e  claustrofobia.  A  maioria  dos  inconvenientes  associados  pode  ser
evitada usando  VNI  por  bocal.  A  VNI  de  circuito  aberto  por  pec¸a  bucal  está  a  ser  usada  por  um
número signiﬁcativo  de  doentes  em  alguns  centros,  na  assistência  ventilatória  diurna  e  como
complemento  da  VNI  noturna  através  de  «máscara». A  VNI  por  pec¸a bucal  é  igualmente  utilizada
durante o  sono  com  o  bucal  ﬁxo  na  posic¸ão,  através  de  uma  orla  de  cobertura  do  lábio.  As  pec¸as
bucais mais  utilizadas  são  as  pequenas  anguladas  de  15  e  22  mm  e  as  de  tipo  «palhinha».
A VNI  através  de  de  pec¸a bucal  é  usada  por  um  número  signiﬁcativo  de  doentes  como  uma
alternativa  eﬁcaz  à  ventilac¸ão  assistida  através  de  tubo  de  traqueostomia  (VTM)  e  está  asso-
ciada à  reduc¸ão  do  risco  de  pneumonias  e  outras  complicac¸ões  respiratórias.  A  sua  utilizac¸ão
facilita a  «acumulac¸ão  de  ar» que  aumenta  a  eﬁcácia  da  tosse,  o  discurso  e  a  compliance  pul-
monar, melhorando  a  qualidade  de  vida  dos  doentes  com  doenc¸as  neuromusculares  (DNM)  em
comparac¸ão as  alternativas  invasivas.  Considerando  estes  benefícios  e  a  disponibilizac¸ão  de
modos ventilatórios  NIV  por  pec¸a bucal,  é  agora  garantido  um  maior  conhecimento  desta  téc-
nica. Esta  revisão  destaca  as  indicac¸ões,  técnicas,  vantagens  e  desvantagens  do  VNI  por  pec¸a
bucal.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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n  1953  Dr.  John  Affeldt  pointed  out  at  a  Round  Table  Con-
erence  on  Poliomyelitis  Equipment,  Roosevelt  Hotel,  New
ork  City,  ‘‘you  can  simply  attach  this  (mouthpiece),  hang  it
y  the  patient,  he  grips  it  by  his  lips,  and  thus  it  allows  for
he  excess  to  blow  off  which  he  doesn’t  want.  It  works  very
ell.  We  even  had  one  patient  who  has  no  breathing  ability
ho  has  fallen  asleep  and  been  adequately  ventilated  by
his  procedure,  so  that  it  appears  to  work  very  well,  and  I
hink  does  away  with  a  lot  of  complications  of  difﬁculty  of
sing  (invasive)  positive  pressure.  You  just  hang  it  by  the
atients  and  they  grip  it  with  their  lips,  when  they  want  it,
nd  when  they  don’t  want  it,  they  let  go  of  it.’’  Thus,  inter-
ittent  positive  pressure  ventilation  (NIV)  via  a  mouthpiece
as  used  as  an  alternative  to  tracheostomy  ventilation
e
F
R
mTMV)  for  patients  requiring  continuous  ventilatory  support
ver  60  years  ago.  Noninvasive  ventilation  reduces  or
liminates  the  work  of  breathing  (WOB),  improves  gas
xchange,  relieves  dyspnea,  rests  inspiratory  muscles,  and
hen  using  mouthpiece  interfaces  can  provide  total  venti-
ator  support1 and  avert  endotracheal  intubation  for  some
atients  during  acute  exacerbations  of  chronic  obstructive
ulmonary  disease  (COPD),2,3 cardiogenic  edema,4 or  neu-
omuscular  respiratory  muscle  failure.5 It  can  prolong  life
nd  preserve  quality  of  life  as  many  patients  become
ontinuous  NIV  (CNIV)  dependent  without
ospitalization.2,5--9 The  noninvasive  interface,  how-
ver,  must  be  comfortable  and  reasonably  air  tight.10,11
ortunately,  there  are  now  over  100  to  choose  from.
eports  of  ‘‘NIV’’  failing  and  resulting  in  intubation  for  as
any  as  77%  of  patients  are  usually  caused  by  inadequate
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Table  1  Main  advantages  and  limits  of  each  type  of  NIV  interface.
Interface  Advantage  Disadvantage
Nasal  Less  risk  of  aspiration,  easier
secretion  clearance
Mouth  leaks,  higher  resistance  through  nasal
passage,  need  for  nasal  patency
Nasal pillows  No  decubitus  Reduces  seal  at  high  pressure  (>15  cmH2O),  nasal
irritation  and  rhinorrhea
Oro-nasal  Better  oral  leak  control  breathing
through  mouth  or  nose,  no  need
for  cooperation
Vomiting,  claustrophobia,  increased  aspiration
risk,  increased  difﬁculty  speaking  eating  and
cough  asphyxiation  if  ventilator  malfunction,
decubitus
Total face May  be  more  comfortable,  rapid  to Difﬁcult  cough  and  communication,  vomiting
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ated  with  CNIV  use  during  waking  hours  for  critical  care  and
long-term  users,  mouthpiece  ventilation  via  15  or  22  mm
mouthpieces  (Fig.  1)  is  the  logical,  more  cosmetic,  andput on
ventilator  settings,  that  is,  the  use  of  bi-level  PAP  at  low
pressure  spans,  skin  pressure  ulcers  from  continuous  mask
instead  daytime  mouthpiece  ventilation,  and/or  failure
to  use  mechanically  assisted  coughing  (MAC)  to  eliminate
airway  secretions.5,12 Failure  can  also  occur  because  of
severe  bulbar  innervated  muscle  dysfunction,  severe  cog-
nitive  impairment  or  lack  of  cooperation,  poor  pulmonary
compliance,  severe  concomitant  lung  or  airways  disease,
and  administration  of  sedative  medications  and/or  supple-
mental  oxygen  therapy.9,11--20 Thus,  appropriate  interface
selection  is  crucial  for  successful  NIV.21 Alternating  different
types  of  interfaces  to  change  skin  pressure  points  relieves
skin  pressure  difﬁculties.22,23 While  Schettino  et  al.24,25
have  raised  concern  about  potential  rebreathing  with  the
total  face  mask,  this  is  not  a  problem  with  open  circuit
ventilation.
While  nasal  and  oro-nasal  interfaces,  including  nasal  pil-
lows  types,  total  face  masks,  and  helmets  (Table  1)26,27 are
useful  for  NIV  use  during  sleep  and  in  critical  care,  they
are  usually  not  practical  for  daytime  support.  Currently,
because  mouthpiece  NIV  is  rarely  tried,  tracheostomy  is
widely  proposed  for  patients  requiring  more  than  nocturnal
plus  daytime  support.  Tracheostomy,  however,  can  increase
health  care  costs,  complications,  has  social  disadvantages,28
and  when  given  the  choice,  patients  never  prefer  it  to  NIV.29
Introduction of mouthpiece NIV
Weakening  patients  who  try  to  discontinue  nasal  NIV  in
the  morning  eventually  continue  it  into  daytime  hours  to
avoid  dyspnea.  Since  this  is  unseemly,  this  is  the  point  at
which  they  should  be  introduced  to  daytime  mouthpiece
NIV.  Flexed  mouthpiece  ﬁxed  adjacent  to  the  mouth  by  a
ﬂexible  support  arm  are  most  convenient  for  air  delivery.
Many  patients  used  simple  mouthpiece  NIV  around-the-clock
since  1953  but  then  in  1968  the  Bennett  lipseal  came  onto
the  American  market.30,31 The  Bennett  Lipseal  ﬁxes  the
mouthpiece  in  the  mouth  for  sleep  and  seals  the  lips  to  pre-
vent  insufﬂated  air  from  leaking  out  of  the  mouth.  Patients
reported  mouthpiece  NIV  to  be  easy  to  apply,  and  simple
to  use  during  activities  of  daily  living  such  as  eating  and
speaking.32
Surprisingly,  this  technology  is  still  not  commonly  used,
and  long-term  survival  for  daytime  use  has  not  been  exten-
sively  documented  for  patients  requiring  ventilator  support
F
a4  h  a  day  other  than  for  one  center  that  has  published  over
00  such  cases  since  1993.28 There  are  no  evidence-based
uidelines  for  this  technique,  and  the  application  is  based
n  the  experience  of  only  a  few  centers28,33--36; thus,  this
eview  aimed  at  highlighting  the  strengths  and  weaknesses
f  this  method.
ationale for and difﬁculties using MPV
hat  are  the  reasons  to  consider  continuous  (24  h/day)  use
f  NIV  rather  than  tracheostomy  for  individuals  who  need
ull-time  ventilatory  support?  Although  tracheostomy  is  nec-
ssary  for  survival  for  patients  with  severe  dysfunction  of  the
lottis  who  have  decreased  upper  airway  patency  and  who
spirate  severely  it  is  simply  unnecessary  for  NMD  patients
ithout  impaired  upper  airway  patency  caused  by  spastic-
ty  or  collapse  of  upper  airways  irrespective  of  extent  of
entilatory  failure.34,35
The  use  of  CNIV  along  with  ancillary  techniques  for
xpelling  airway  secretions  can  avert  the  need  for  haz-
rdous  endotracheal  intubations  for  many.  Translaryngeal  as
ell  as  tracheostomy  tubes,  especially  with  inﬂated  cuffs,
an  ulcerate  tracheal  tissues  and  result  in  tracheal  steno-
is,  trachiectasis,  hemorrhage,  ﬁstulae,  and  perforations.
urther,  cartilage  damage  and  loss  of  structural  integrity
ncrease  tracheal  collapsibility  (tracheomalacia).37--40 Inva-
ive  ventilation  is  also  associated  with  a  high  incidence
f  pneumonia  due  to  the  tube  and  airway  colonization
ith  pathogenic  bacteria.  The  tubes  also  impair  mucociliary
learance.41--43Likewise,  because  of  the  difﬁculties  associ-igure  1  Patient  using  noninvasive  ventilation  via  15  mm
ngled  mouthpiece  with  its  circuit  adapter.
2 G.  Garuti  et  al.
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omfortable  alternative  but  requires  more  active  partic-
pation  than  the  use  of  facemasks.  It  has  the  following
dvantages:
1)  less  negative  impact  on  the  patient
2)  no  risk  of  skin  breakdown
3)  facilitates  speech
4)  facilitates  eating  and  swallowing
5)  better  appearance  and
6)  is  safer  by  permitting  use  of  glossopharyngeal  breathing
in  the  event  of  sudden  ventilator  failure  or  accidental
disconnection  from  the  ventilator.
Custom-molded  bite-plates  have  also  been  constructed
or  mouthpiece  NIV  with  and  without  retention  straps.28,44
ach  et  al.  also  reported  the  use  of  daytime  mouthpiece  NIV
n  combination  with  lipcovering  custom-molded  orthodontic
ite  plates  for  mouthpiece  NIV  use  overnight.27 In  one  study,
outhpiece  NIV  was  reported  for  patients  with  cystic  ﬁbrosis
nd  acute  and  chronic  respiratory  failure.45 More  recently,
outhpiece  NIV  was  reported  to  be  as  effective  as  a  full-
ace  mask  NIV  in  reducing  inspiratory  effort  for  treating
RF.46
Mouthpieces  for  daytime  use  may  elicit  salivation  and
ong-term  use  can  cause  orthodontic  deformities  after  20--
0  years  use.26,27 Nasal  pledges  or  nose  clips  can  be  used
o  avoid  air  leak  through  the  nares  for  patients  using  lip-
overing  interfaces  for  mouthpiece  NIV  during  sleep.26,27
owever,  air  may  also  be  swallowed  and  cause  gastric  dis-
ension.  Recently,  because  of  the  availability  of  so  many
elf-molding  designs,  custom-molded  bite-plate  interfaces
ave  been  almost  completely  abandoned.47
Since  mouthpiece  and  nasal  NIV  are  open  systems  of  ven-
ilator  support,  the  low  pressure  alarms  of  ventilators  not
aving  mouthpiece  NIV  modes  can  often  be  sound.  How-
ver,  back  pressure  from  a  15  mm  angled  mouthpiece  is
ufﬁcient  to  prevent  a  low-pressure  alarm  set  at  2  cmH2O.
ssist  control  mode  with  a  physiological  back-up  rate  is  rec-
mmended  so  that  every  breath  triggers  supplemental  air
rom  the  ventilator.48 The  patient  triggers  the  breath  by
lacing  the  mouth  on  the  mouthpiece  and  creating  a  small
egative  pressure  in  the  circuit  by  sipping  or  inhaling.48,49
ith  the  ‘‘kiss  trigger’’  on  mouthpiece  mode  of  the  Tril-
gy  ventilator  (Philips-Respironics  Inc.)  all  the  patient  has
o  do  is  to  touch  it  for  air  delivery.  No  back-up  rate  is
eeded  for  daytime  use  so  no  air  blows  into  the  patients’
aces.
ypes of ventilators for open circuit
outhpiece ventilation
olume  cycling  of  portable  ventilators  in  assist-control
ode48--50 both  provides  ventilatory  support  and  permits  air
tacking.  Pressure  cycling  in  assist  control  mode,  also  using
ctive  ventilator  circuits,  can  be  used  as  well  but  does  not
ermit  air  stacking.  Since  the  patient  can  take  as  much  of
he  delivered  air  as  wanted  for  speech,  shouting,  eating,
oughing,  etc.,  volumes  are  set  from  700  to  1500  mL  for
dult  patients.50,51 The  mouthpiece  can  be  mounted  close
o  the  head  so  that  the  patient  can  grab  it  as  desired.47--49
ir  stacking  is  done  by  taking  multiple  volumes  without
t
a
i
tFigure  2  Open  mouthpiece  ventilation  dedicated  circuit.
xhaling  thereby  increasing  lung  volumes  to  maintain  pul-
onary  compliance  and  cough  more  effectively.28,51,52 Using
 volume  cycling  ventilator  the  NIV  user  can  air  stack
ndependently.  In  this  manner,  a  NMD  patient  who  has  an
neffective  cough  can  often  produce  a  peak  cough  ﬂow  (PCF)
ufﬁcient  to  clear  airway  secretions  as  needed.53
Mouthpiece  NIV  can  be  used  for  diseases  other  than
MDs.54--59 Currently,  in  Europe,  volume-cycling  portable
entilators  are  uncommon.  Thus,  ventilators  usually  pres-
ure  set  and  include:  the  Resmed  Elisee  150,  Breas  Vivo  50
nd  Resmed  VS  III  with  mouthpiece  platform.  The  Philips
espironics  Trilogy  with  its  dedicated  mouthpiece  NIV  mode
s  used  with  a  single  active  circuit  with  an  exhalation  valve
Fig.  2).
ncillary techniques
ong-term  CNIV  including  mouthpiece  NIV  cannot  be
uccessful  without  mechanical  insufﬂation--exsufﬂation
mechanically  assisted  coughing  or  MAC)  used  to  increase
ough  ﬂows  for  patients  with  respiratory  muscle  weakness.
he  MAC  can  increase  PCF  from  being  negligible  and
neffective  to  over  300  L/m  to  thereby  clear  the  airways  of
ebris  and  prevent  or  return  oxyhemoglobin  saturation  to
ormal  levels,  thereby  averting  ARF  and  intubation  or  per-
itting  intubated  patients  and  patients  with  tracheostomyubes  who  have  little  or  no  ventilator-free  breathing
bility  the  possibility  of  being  extubated  without  undergo-
ng  tracheotomy  or  being  decanulated  of  any  tracheostomy
ubes.60--62
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The  clinical  evidence
The  most  common  indication  for  mouthpiece  NIV  is  for
NMD.  It  was  initially  used  for  daytime  ventilatory  sup-
port  for  ventilator-dependent  post-poliomyelitis  and  NMD
patients  who  were  otherwise  continuously  dependent  on
iron-lungs  in  the  1950s  and  1960s.50 CNIV  has  continued  to
be  used  by  these  and  other  patients  in  and  around  the  same
centers.63,64
In neuromuscular diseases
In  a  1993  study  of  257  patients  with  acute  or  chronic  respi-
ratory  failure,  NIV  via  mouthpiece  was  reported  as  the
predominant  ventilatory  support  during  the  day  and  it  was
used  with  lipcover  phalange  for  sleep  by  163  of  the  257
patients.  Sixty-one  of  them  had  little  or  no  measurable
vital  capacity.28 In  a  cohort  study,  Bach  et  al.  compared
24  patients  using  NIV  (14  of  them  CNIV  dependent  with
22  patients  using  continuous  (C)  TMV).  The  CNIV  users
had  signiﬁcantly  fewer  hospitalization  days  per  year  (d/Y)
(2.3  ±  2.4  d/y/patient  vs.  0.3  ±  2.4  d/y/patient,  p  ≤  0.04)
and  hospitalizations/year/patient  (0.3  ±  0.4  vs.  0.1  ±  0.4).64
In  a  retrospective  study  of  Gomez-Merino  et  al.,  patients
with  DMD  who  used  CNIV  along  with  a  protocol  of  home
management  of  secretion  expulsion  by  MAC  were  compared
to  a  group  that  did  not  have  access  to  the  protocol  and
were  tracheostomized.12 The  protocol  consisted  of  using  air
stacking,  mouthpiece  NIV  for  daytime  support,  nasal  NIV  for
sleep,  and  MAC  to  maintain  oxyhemoglobin  saturation  >  94%
using  a  pulse  oximeter  at  home.  Among  the  34  CNIV  users
with  access  to  the  protocol  3  of  them  died  from  heart  fail-
ure  and  none  from  respiratory  complications.  Among  the
31  patients  who  did  not  have  access  to  the  protocol  27
died:  20  from  respiratory  failure  and  7  from  heart  failure.
A  consensus  statement  of  the  American  Thoracic  Society  on
respiratory  care  in  DMD  supports  this  method  for  preventing
and  treating  acute  and  chronic  respiratory  failure.65
A  management  protocol  of  NIV  with  follow-up  of  12  years
for  23  DMD  and  6  post-polio  patients  was  published  by  Cur-
ran  et  al.  with  progressive  generalized  muscle  weakness
and  decreasing  vital  capacity  from  an  average  of  482  mL
to  336  mL  the  DMD  group  required  an  average  increase  of
0.95  h  per  day  of  mouthpiece  NIV  use  per  year.  The  aver-
age  overall  survival  increased  from  19  years  and  9  months
to  25  years  and  9  months  with  ventilator  use  in  that  study
but  the  patients  did  not  have  access  to  MAC.66 Ishikawa
et  al.  demonstrated  mean  survival  to  39.6  years  of  age  for
88  patients  with  DMD  treated  with  CNIV  including  mouth-
piece  ventilation  vs.  to  28.1  years  of  age  for  21  treated
by  CTMV.67 Toussaint  et  al.  reported  diurnal  use  of  mouth-
piece  NIV  in  a  regimen  of  CNIV  that  improved  survival  rates
in  DMD  to  88,  77,  58  and  51%  after  1,  3,  5  and  7  years,
respectively  with  mean  survival  to  31  years  of  age  for  a total
of  184  patient-years.68 More  recently,  Villanova  reported
that  19  DMD  patients  depended  on  CNIV  for  a  total  of  329
patient-years,  up  to  16  years  in  one  case.69 The  patients
became  CNIV  dependent  once  their  VCs  had  decreased  below
297  ±  113  ml.69 In  2013  McKim  et  al.  reported  prolongation
of  survival  by  an  average  of  5.7  years  for  12  DMD  patients
by  CNIV.34
a
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n respiratory failure from other disorders
wenty-nine  COPD  patients  treated  with  NIV  via  mouth-
iece  were  matched  to  29  patients  who  received  NIV  and
tandard  medical  treatment.  At  admission,  age,  PaCO2,  and
H  were  recorded.  The  two  groups  had  similar  PaCO2 and
H  at  admission  (78.6  ±  12  mmHg  and  7.30  ±  0.04  mouth-
iece  NIV  group,  79.8  ±  12  mmHg  and  7.29  ±  0.04  nasal
ask  NIV  group).  Mouthpiece  NIV  use  averted  need  for
ndotracheal  intubation  for  27  of  the  29  patients  and
asal  mask  NIV  for  25  of  29  patients.  At  the  end  of  the
reatment  protocol,  the  PaCO2 was  lower  in  the  mouth-
iece  NIV  (62.2  ±  9.6  mmHg)  compared  to  the  other  group
72.4  ±  20.4  mmHg,  p  <  0.018).  This  study  shows  that  in  the
ase  of  moderate  respiratory  acidosis,  NIV  via  mouthpiece
igniﬁcantly  reduces  the  need  for  endotracheal  intubation
ompared  with  standard  medical  therapy  and  can  be  an
lternative  to  nasal  NIV  especially  when  the  latter  is  poorly
olerated.59
One  study  focused  on  daytime  mouthpiece  NIV  and  noc-
urnal  nasal  NIV  for  a  group  of  113  adults  with  cystic  ﬁbrosis
nd  chronic  respiratory  failure  and  reported  probable  suc-
essfully  sustaining  life  until  lung  transplantation  became
vailable  to  them.
Mouthpiece  ventilation  was  also  compared  with  face-
ask  ventilation  for  patients  in  respiratory  failure  due  to
hronic  obstructive  respiratory  diseases  and  cardiogenic
nsufﬁciency.  NIV  delivered  by  both  facemask  or  mouthpiece
ncreased  pH  and  lowered  paCO2 and  averted  need  for  endo-
racheal  intubations.54 Recently  mouthpiece  ventilation  has
lso  been  proposed  in  the  treatment  of  severe  sleep  related
reathing  disorders.55--58
dvantages  and  disadvantages  of  mouthpiece
entilation
he  most  important  advantage  of  using  a  mouthpiece  for
ssisting  ventilation  is  that  there  is  less  interference  with
peech,  very  little  dead  space,  better  appearance,  and
o  need  for  headgear,  thereby  eliminating  any  possibility
f  claustrophobia.  The  greatest  disadvantage  is  its  limi-
ation  to  being  useful  predominantly  for  waking  hours28,47
xcept  when  retained  by  a  lip  covering  interface  like  the
ipseal  or  Oracle.  Another  disadvantage  which  could  limit
ts  use  for  ARF  are  nasal  leaks,34,46,70 but  mouth  air  leaks
an  be  controlled  with  a tight-ﬁtting  lip  seal  and  nasal
ledges  or  nose  clips  can  be  used  to  avoid  air  leak  via  the
ares.47,70
Positive  expiratory  pressure  (EPAP  or  PEEP)  cannot  be
aintained  for  patients  using  open  systems  of  NIV  and,
ndeed,  are  rarely  if  ever  needed  for  these  patients.
bstructive  apneas  are  relieved  by  sufﬁcient  positive  inspi-
atory  pressure  delivery.  Apnea  alarms,  when  present,
hould  be  set  at  the  highest  threshold  to  avoid  unnecessary
ctivation  and  nuisance.  The  most  common  ventilator  mode
sed  is  assist  volume-controlled  (ACV)  with  tidal  volume
etween  0.7  and  1.5  L  with  no  PEEP  (EPAP),  low  pressure
larm  set  at  the  minimum  and  maximum  apnea  duration50
Table  2).  Although  volume  cycling  permits  air  stacking,
hen  gastric  inﬂation  is  severe,  volume  cycling  is  discon-
inued  in  favor  of  pressure  cycling.  For  some  patients,  a
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Table  2  Example  of  ventilator  setting.
ACV  (assisted/controlled  in  volume)
Setting
VT 700--1200  mL
PEEP  0
I/E  ratio  1:2
Frequency  of  breathing:  6  breaths
Trigger:  1--2(low)
Flow  shape:  3
ALARMS
Frequency  of  breathing  1
Pmax 60  cmH2O
Pmin 0
VTmin ml 20  ml
VT, tidal volume Pmin, minimal pressure; PEEP, positive end expi-
ratory pressure; VTmin, minimal tidal volume; Pmax, maximal
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astrostomy  is  required  so  that  air  insufﬂated  into  the  stom-
ch  can  be  ‘‘burped  out’’  during  sleep.  Mouthpiece  NIV  is  not
uccessful  when  patients  are  uncooperative,  cannot  access
he  interface,  or  when  a  severe  bulbar  dysfunction  causes
spiration  of  saliva  such  that  the  O2 saturation  baseline
emains  below  95%.  It  can  cause  or  exacerbate  dry  mouth.
uch  patients  may  beneﬁt  from  heated  humidiﬁcation  or
witching  to  oro-nasal  interfaces.
onclusions
ome  authors  think  that  tracheostomy  is  more  secure  for
ontinuous  ventilator  support  despite  signiﬁcantly  longer
urvival  and  fewer  complications  using  NIV.35 Daytime
outhpiece  NIV  in  a  regimen  of  CNIV  support  is  a  safe  and
cceptable  alternative  to  CTMV.  There  is  widespread  agree-
ent  that  NIV  is  preferable  to  TMV  during  the  early  stages
f  DMD  ventilatory  insufﬁciency,  but  there  continues  to  be
idespread  ignorance  of  its  beneﬁts  over  invasive  manage-
ent  for  continuously  dependent  patients.  The  swallowing
nd  speech  difﬁculties  associated  with  tracheostomy  are
voided  by  mouthpiece  NIV.  Patients  with  DMD  and  other
MDs  should  be  offered  diurnal  NIV  via  a  mouthpiece  when
octurnal-only  NIV  becomes  inadequate  (Fig.  3).  If  mouth-
iece  NIV  and  MAC  are  not  available  at  many  medical
enters,71,72 it  can  become  available  by  ordering  the  appro-
riate  equipment  and  training  the  staff.  Hopefully,  this  brief
eview  will  encourage  many  such  centers  to  invest  in  this.
t  should  also  be  noted  that  the  access  to  the  resources
ecessary  to  support  patients  living  at  home  with  TMV  vary
reatly  throughout  Europe,  so  mouthpiece  NIV  may  be  espe-
ially  valuable  in  countries  where  these  resources  are  scarce
nd  there  is  a  total  or  partial  lack  of  respiratory  home  care
ervices.
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